Brind.

Theriva presented new clinical data at both the ESMO 2025 Congress and the ASCO 2025 Annual Meeting.

1 report, 1 independent Updated Aug 11

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

American Society of Clinical Oncology European Society for Medical Oncology

Keep exploring

The entities involved

American Society of Clinical Oncology
organization

Nothing else this week.
European Society for Medical Oncology
Professional organisation

Nothing else this week.

Related events

Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.Sep 21

Coverage

Newest first; wire copies grouped

Aug 11GlobeNewswireTheriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expa